Keros Therapeutics (KROS) Net Cash Flow (2019 - 2025)

Keros Therapeutics has reported Net Cash Flow for 7 years, with the latest figure at -$406.1 million in Q4 2025.

• For the quarter ending Q4 2025, Net Cash Flow fell 1488.37% year-over-year to -$406.1 million; the trailing twelve-month figure through Dec 2025 stood at -$272.5 million (down 218.99% YoY), and the FY2025 full-year result was -$272.5 million, down 218.99% from the prior year.
• Net Cash Flow for Q4 2025 stood at -$406.1 million, down from $3.3 million in the prior quarter.
• The five-year high for Net Cash Flow was $160.6 million in Q1 2025, with the low at -$406.1 million in Q4 2025.
• Historically, Net Cash Flow has averaged $1.1 million across 5 years, with a median of $900500.0 in 2022.
• Annual changes were most pronounced in 2023 — Net Cash Flow jumped 5071.22% — and 2025, when it slumped 1488.37%.
• Keros Therapeutics' Net Cash Flow stood at $8.7 million in 2021, then surged by 355.84% to $39.6 million in 2022, then grew by 9.17% to $43.3 million in 2023, then plunged by 32.38% to $29.2 million in 2024, then tumbled by 1488.37% to -$406.1 million in 2025.
• The last three Net Cash Flow figures came in at -$406.1 million (Q4 2025), $3.3 million (Q3 2025), and -$30.3 million (Q2 2025), per Business Quant data.